PRISM BioLab Co

PRISM BioLab Co ROE

The Return on Equity (ROE) of PRISM BioLab Co (206A.T) as of Nov 10, 2026 is -30.78 %. In the previous year, Return on Equity (ROE) was -29.96 % — a change of 2.72% (lower).

ROE

-30.78 %

YoY

2.72%

Last updated:

In 2025, PRISM BioLab Co's return on equity (ROE) was -30.78 %, a 2.72% increase from the -29.96 % ROE in the previous year.

The PRISM BioLab Co ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2022
4.36 JPY
Jan 1, 2023
-45.90 JPY
Jan 1, 2024
-29.96 JPY
Jan 1, 2025
-30.78 JPY
The PRISM BioLab Co ROE history
YEARROEYoY
-30.78 %+2.72%
-29.96 %-34.72%
-45.90 %-1,153.64%
4.36 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

PRISM BioLab Co Stock analysis

What does PRISM BioLab Co do? PRISM BioLab Co Ltd generates revenue through two distinct business models in the pharmaceuticals sector. The in-house development business focuses on selecting drug discovery targets and creating programs internally using their PepMetics technology platform. The joint development business collaborates with pharmaceutical companies to develop drug discovery programs leveraging their proprietary PepMetics technology. Both models utilize the company's owned drug discovery platform to create new pharmaceutical products. The company's primary clients are pharmaceutical companies seeking to develop new drugs through partnerships with PRISM BioLab's technology. PRISM BioLab's business model centers on its PepMetics technology, which serves as the foundation for both its in-house development and joint development segments. The company builds new drug discovery platforms and develops new drugs through these segments, targeting pharmaceutical companies as their main customers. The firm's research and development activities are conducted using their owned technology, which differentiates their approach in the drug discovery market. The company's revenue streams are derived from pharmaceutical companies that partner with PRISM BioLab for drug discovery programs. By utilizing their PepMetics technology platform, the company creates targeted drug discovery solutions that are developed either internally or in collaboration with pharmaceutical partners. This approach allows PRISM BioLab to generate income through both direct development efforts and collaborative projects with industry clients. PRISM BioLab Co is one of the most popular companies on Eulerpool.

ROE Details

Decoding PRISM BioLab Co's Return on Equity (ROE)

PRISM BioLab Co's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing PRISM BioLab Co's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

PRISM BioLab Co's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in PRISM BioLab Co’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about PRISM BioLab Co stock

Return on Equity (ROE) of PRISM BioLab Co is -30.78 % in 2025.

Return on Equity (ROE) of PRISM BioLab Co changed from -29.96 % to -30.78 %, representing a 2.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) PRISM BioLab Co since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s PRISM BioLab Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — PRISM BioLab Co

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — PRISM BioLab Co